216 related articles for article (PubMed ID: 38487542)
1. Directing the migration of serum-free,
Parwani KK; Branella GM; Burnham RE; Burnham AJ; Bustamante AYS; Foppiani EM; Knight KA; Petrich BG; Horwitz EM; Doering CB; Spencer HT
Front Immunol; 2024; 15():1331322. PubMed ID: 38487542
[TBL] [Abstract][Full Text] [Related]
2. Protective role of the inflammatory CCR2/CCL2 chemokine pathway through recruitment of type 1 cytotoxic γδ T lymphocytes to tumor beds.
Lança T; Costa MF; Gonçalves-Sousa N; Rei M; Grosso AR; Penido C; Silva-Santos B
J Immunol; 2013 Jun; 190(12):6673-80. PubMed ID: 23686489
[TBL] [Abstract][Full Text] [Related]
3. Ex Vivo Expanded Human Vγ9Vδ2 T-Cells Can Suppress Epithelial Ovarian Cancer Cell Growth.
Mao TL; Miao CH; Liao YJ; Chen YJ; Yeh CY; Liu CL
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30845699
[TBL] [Abstract][Full Text] [Related]
4. Role of monocyte chemotactic protein-1/CC chemokine ligand 2 on gamma delta T lymphocyte trafficking during inflammation induced by lipopolysaccharide or Mycobacterium bovis bacille Calmette-Guérin.
Penido C; Vieira-de-Abreu A; Bozza MT; Castro-Faria-Neto HC; Bozza PT
J Immunol; 2003 Dec; 171(12):6788-94. PubMed ID: 14662884
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib enhances cytotoxicity of ex vivo-expanded gamma delta T cells against acute myeloid leukemia and T-cell acute lymphoblastic leukemia.
Story JY; Zoine JT; Burnham RE; Hamilton JAG; Spencer HT; Doering CB; Raikar SS
Cytotherapy; 2021 Jan; 23(1):12-24. PubMed ID: 33168453
[TBL] [Abstract][Full Text] [Related]
6. Involvement of CC chemokines in gammadelta T lymphocyte trafficking during allergic inflammation: the role of CCL2/CCR2 pathway.
Penido C; Costa MF; Souza MC; Costa KA; Candéa AL; Benjamim CF; Henriques Md
Int Immunol; 2008 Jan; 20(1):129-39. PubMed ID: 18056919
[TBL] [Abstract][Full Text] [Related]
7. Zoledronate sensitizes neuroblastoma-derived tumor-initiating cells to cytolysis mediated by human γδ T cells.
Nishio N; Fujita M; Tanaka Y; Maki H; Zhang R; Hirosawa T; Demachi-Okamura A; Uemura Y; Taguchi O; Takahashi Y; Kojima S; Kuzushima K
J Immunother; 2012 Oct; 35(8):598-606. PubMed ID: 22996365
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer.
Xu Y; Xiang Z; Alnaggar M; Kouakanou L; Li J; He J; Yang J; Hu Y; Chen Y; Lin L; Hao J; Li J; Chen J; Li M; Wu Q; Peters C; Zhou Q; Li J; Liang Y; Wang X; Han B; Ma M; Kabelitz D; Xu K; Tu W; Wu Y; Yin Z
Cell Mol Immunol; 2021 Feb; 18(2):427-439. PubMed ID: 32939032
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets.
Sordi V; Malosio ML; Marchesi F; Mercalli A; Melzi R; Giordano T; Belmonte N; Ferrari G; Leone BE; Bertuzzi F; Zerbini G; Allavena P; Bonifacio E; Piemonti L
Blood; 2005 Jul; 106(2):419-27. PubMed ID: 15784733
[TBL] [Abstract][Full Text] [Related]
10. Homing characteristics of donor T cells after experimental allogeneic bone marrow transplantation and posttransplantation therapy for multiple myeloma.
van der Voort R; Volman TJ; Verweij V; Linssen PC; Maas F; Hebeda KM; Dolstra H
Biol Blood Marrow Transplant; 2013 Mar; 19(3):378-86. PubMed ID: 23266741
[TBL] [Abstract][Full Text] [Related]
11. Ex vivo expanded human Vgamma9Vdelta2+ gammadelta-T cells mediate innate antitumor activity against human prostate cancer cells in vitro.
Liu Z; Guo BL; Gehrs BC; Nan L; Lopez RD
J Urol; 2005 May; 173(5):1552-6. PubMed ID: 15821484
[TBL] [Abstract][Full Text] [Related]
12. In vivo expansion and activation of γδ T cells as immunotherapy for refractory neuroblastoma: A phase 1 study.
Pressey JG; Adams J; Harkins L; Kelly D; You Z; Lamb LS
Medicine (Baltimore); 2016 Sep; 95(39):e4909. PubMed ID: 27684826
[TBL] [Abstract][Full Text] [Related]
13. Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded Vgamma9Vdelta2 T cells from renal cell carcinoma patients.
Viey E; Lucas C; Romagne F; Escudier B; Chouaib S; Caignard A
J Immunother; 2008 Apr; 31(3):313-23. PubMed ID: 18317356
[TBL] [Abstract][Full Text] [Related]
14. Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain.
Izumi T; Kondo M; Takahashi T; Fujieda N; Kondo A; Tamura N; Murakawa T; Nakajima J; Matsushita H; Kakimi K
Cytotherapy; 2013 Apr; 15(4):481-91. PubMed ID: 23391461
[TBL] [Abstract][Full Text] [Related]
15. Recruitment of γδ T cells to the lesion via the CCL2/CCR2 signaling after spinal cord injury.
Xu P; Zhang F; Chang MM; Zhong C; Sun CH; Zhu HR; Yao JC; Li ZZ; Li ST; Zhang WC; Sun GD
J Neuroinflammation; 2021 Mar; 18(1):64. PubMed ID: 33653377
[TBL] [Abstract][Full Text] [Related]
16. TGF-β1 potentiates Vγ9Vδ2 T cell adoptive immunotherapy of cancer.
Beatson RE; Parente-Pereira AC; Halim L; Cozzetto D; Hull C; Whilding LM; Martinez O; Taylor CA; Obajdin J; Luu Hoang KN; Draper B; Iqbal A; Hardiman T; Zabinski T; Man F; de Rosales RTM; Xie J; Aswad F; Achkova D; Joseph CR; Ciprut S; Adami A; Roider HG; Hess-Stumpp H; Győrffy B; Quist J; Grigoriadis A; Sommer A; Tutt ANJ; Davies DM; Maher J
Cell Rep Med; 2021 Dec; 2(12):100473. PubMed ID: 35028614
[TBL] [Abstract][Full Text] [Related]
17. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
[TBL] [Abstract][Full Text] [Related]
18. The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities.
Ponte AL; Marais E; Gallay N; Langonné A; Delorme B; Hérault O; Charbord P; Domenech J
Stem Cells; 2007 Jul; 25(7):1737-45. PubMed ID: 17395768
[TBL] [Abstract][Full Text] [Related]
19. An optimized cultivation method for future
Bold A; Gross H; Holzmann E; Knop S; Hoeres T; Wilhelm M
Front Immunol; 2023; 14():1185564. PubMed ID: 37539052
[TBL] [Abstract][Full Text] [Related]
20. Cancer immunotherapy with γδ T cells: many paths ahead of us.
Kabelitz D; Serrano R; Kouakanou L; Peters C; Kalyan S
Cell Mol Immunol; 2020 Sep; 17(9):925-939. PubMed ID: 32699351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
